Moonlake Immunotherapeutics
A clinical-stage biopharmaceutical company based in Switzerland that develops immunotherapies. The grounding search tool was unavailable during this attempt, so no verified facts could be retrieved; please retry the request to obtain a properly sourced description.
Sold 3.75M
Sold 350.0K
Sold 352.9K
Sold 6.50M
Granted 354.3K · Bought 10.9K · Sold 160.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Biotechnology Value Fund II LP +9 co-filersDirector, 10% owner, Director, See Explanation of Responses · 3 transactions | +412.5% | 6.60M | — | — | 3.75M |
| Santos da Silva JorgeChief Executive Officer, Director · 6 transactions | -11.4% | 2.92M | — | — | 350.0K |
| Reich KristianChief Scientific Officer · 9 transactions | -9.6% | 2.86M | — | — | 352.9K |
| Chen Bihua +5 co-filersFormer 10% Owner · 5 transactions | -76.5% | 1.99M | — | — | 6.50M |
| Bodenstedt MatthiasChief Financial Officer · 11 transactions | +21.3% | 1.12M | 354.3K | 10.9K | 160.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -11.10M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.